Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Sograzepide
Price:
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang

ShangHai DC Chemicals Co.,Ltd
China
Product Name: Netazepide
Price: ￥Inquiry/1g
Purity: 98.9%
Stocking Period: 1 Day
Contact: Tony Lai

DC Chemicals Limited
China
Product Name: Netazepide
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

155488-25-8

155488-25-8 structure

155488-25-8 structure

Name: Sograzepide
Chemical Name: 1-[(3R)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3H-1,4-benzodiazepin-3-yl]-3-[3-(methylamino)phenyl]urea
CAS Number: 155488-25-8
Molecular Formula: C₂₈H₃₀N₆O₃
Molecular Weight: 498.57600
Catalog: Signaling Pathways GPCR/G Protein Cholecystokinin Receptor
Create Date: 2018-06-13 11:42:15
Modify Date: 2024-01-02 00:26:49
Sograzepide (Netazepide;YF476) is a gastrin/cholecystokinin 2 receptor (CCK2) antagonist.

Name	1-[(3R)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-pyridin-2-yl-3H-1,4-benzodiazepin-3-yl]-3-[3-(methylamino)phenyl]urea
Synonyms	UNII-HOU4I0G29C YF-476 Sograzepide

Description	Sograzepide (Netazepide;YF476) is a gastrin/cholecystokinin 2 receptor (CCK2) antagonist.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Cholecystokinin Receptor Research Areas >> Metabolic Disease
Target	Gastrin/cholecystokinin 2 receptor (CCK2)[1]
References	[1]. Boyce M, et al. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects. Br J Clin Pharmacol. 2015 May;79(5):744-55.

Density	1.25g/cm3
Boiling Point	723.049ºC at 760 mmHg
Molecular Formula	C₂₈H₃₀N₆O₃
Molecular Weight	498.57600
Flash Point	391.086ºC
Exact Mass	498.23800
PSA	119.28000
LogP	4.04840
Storage condition	2-8℃

42471-56-7 structure

42471-56-7

~%

155488-25-8 structure

155488-25-8

Literature: Journal of Medicinal Chemistry, , vol. 40, # 3 p. 331 - 341

99-05-8 structure

99-05-8

~%

155488-25-8 structure

155488-25-8

Literature: Journal of Medicinal Chemistry, , vol. 40, # 3 p. 331 - 341

111331-82-9 structure

111331-82-9

~%

155488-25-8 structure

155488-25-8

Literature: Journal of Medicinal Chemistry, , vol. 40, # 3 p. 331 - 341

152665-84-4 structure

152665-84-4

~%

155488-25-8 structure

155488-25-8

Literature: Journal of Medicinal Chemistry, , vol. 40, # 3 p. 331 - 341

168162-22-9 structure

168162-22-9

~%

155488-25-8 structure

155488-25-8

Literature: Journal of Medicinal Chemistry, , vol. 40, # 3 p. 331 - 341

168162-30-9 structure

168162-30-9

~%

155488-25-8 structure

155488-25-8

Literature: Journal of Medicinal Chemistry, , vol. 40, # 3 p. 331 - 341

168162-32-1 structure

168162-32-1

~%

155488-25-8 structure

155488-25-8

Literature: Journal of Medicinal Chemistry, , vol. 40, # 3 p. 331 - 341

164343-31-1 structure

164343-31-1

~%

155488-25-8 structure

155488-25-8

Literature: Journal of Medicinal Chemistry, , vol. 40, # 3 p. 331 - 341

186086-59-9 structure

186086-59-9

~%

155488-25-8 structure

155488-25-8

Literature: Journal of Medicinal Chemistry, , vol. 40, # 3 p. 331 - 341

Precursor 8
42471-56-7 99-05-8 111331-82-9 152665-84-4
168162-22-9 168162-30-9 164343-31-1 186086-59-9
DownStream 0